Developments NLS launches preclinical program for Mazindol ER in fentanyl addiction NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and... January 28, 2025